Ligand Pharmaceuticals Inc (LGND)
121.08
-8.82
(-6.79%)
USD |
NASDAQ |
Nov 08, 16:00
121.08
0.00 (0.00%)
After-Hours: 16:54
Ligand Pharmaceuticals Revenue (TTM): 133.48M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 133.48M |
| March 31, 2024 | 118.31M |
| December 31, 2023 | 131.31M |
| September 30, 2023 | 153.60M |
| June 30, 2023 | 179.95M |
| March 31, 2023 | 203.71M |
| December 31, 2022 | 196.24M |
| September 30, 2022 | 182.75M |
| June 30, 2022 | 188.36M |
| March 31, 2022 | 222.91M |
| December 31, 2021 | 241.54M |
| September 30, 2021 | 251.79M |
| June 30, 2021 | 228.81M |
| March 31, 2021 | 185.55M |
| December 31, 2020 | 163.56M |
| September 30, 2020 | 143.43M |
| June 30, 2020 | 126.39M |
| March 31, 2020 | 109.96M |
| December 31, 2019 | 120.28M |
| September 30, 2019 | 152.87M |
| June 30, 2019 | 173.72M |
| March 31, 2019 | 238.78M |
| December 31, 2018 | 251.45M |
| September 30, 2018 | 242.33M |
| June 30, 2018 | 230.04M |
| Date | Value |
|---|---|
| March 31, 2018 | 167.99M |
| December 31, 2017 | 141.10M |
| September 30, 2017 | 128.82M |
| June 30, 2017 | 117.07M |
| March 31, 2017 | 108.59M |
| December 31, 2016 | 108.97M |
| September 30, 2016 | 91.98M |
| June 30, 2016 | 88.06M |
| March 31, 2016 | 86.96M |
| December 31, 2015 | 71.91M |
| September 30, 2015 | 73.72M |
| June 30, 2015 | 70.99M |
| March 31, 2015 | 63.18M |
| December 31, 2014 | 64.54M |
| September 30, 2014 | 56.28M |
| June 30, 2014 | 54.31M |
| March 31, 2014 | 53.28M |
| December 31, 2013 | 48.97M |
| September 30, 2013 | 47.87M |
| June 30, 2013 | 41.24M |
| March 31, 2013 | 37.40M |
| December 31, 2012 | 31.39M |
| September 30, 2012 | 30.69M |
| June 30, 2012 | 30.06M |
| March 31, 2012 | 31.78M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
109.96M
Minimum
Mar 2020
251.79M
Maximum
Sep 2021
172.73M
Average
179.95M
Median
Jun 2023
Revenue (TTM) Benchmarks
| Regeneron Pharmaceuticals Inc | 13.85B |
| Agios Pharmaceuticals Inc | 32.87M |
| ADMA Biologics Inc | 330.24M |
| Pieris Pharmaceuticals Inc | -- |
| AnaptysBio Inc | 57.17M |